ACTA1 and Peritoneal Fibrosis: Intraperitoneal administration of liposome nanoparticles encapsulating TGF-β1-siRNA knocked down TGF-β1 expression in the peritoneum and inhibited peritoneal fibrosis, associated with decreased proliferation of α-SMA-positive myofibroblasts derived from different cell types, including mesothelial and bone marrow-derived cells [39].